Chemoresistance and resistance to targeted therapies in biliary tract cancer: what have we learned?
Christian MayrTobias KiesslichDominik Paul ModestSebastian StintzingMatthias OckerDaniel NeureiterPublished in: Expert opinion on investigational drugs (2022)
experimental systems is not yet available. Additionally, a reliable monitoring of therapy-relevant cellular changes needs to be established which allows for choosing the optimal drug (combination) before and/or during pharmacological therapy.